Transcend Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Transcend Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.18M	Buy	55,185 +876	+2%	+$50.3K	0.21%	90
2026 Q1	$3.29M	Sell	54,309 -2,348	-4%	-$137K	0.26%	70
2025 Q4	$3.06M	Sell	56,657 -2,872	-5%	-$138K	0.24%	87
2025 Q3	$2.68M	Buy	59,529 +1,953	+3%	+$91.2K	0.19%	116
2025 Q2	$2.67M	Sell	57,576 -43,496	-43%	-$2.14M	0.21%	115
2025 Q1	$6.16M	Sell	101,072 -94,725	-48%	-$5.52M	0.44%	46
2024 Q4	$11.1M	Sell	195,797 -3,965	-2%	-$222K	0.8%	24
2024 Q3	$10.3M	Sell	199,762 -1,318	-0.7%	-$61.8K	0.69%	30
2024 Q2	$8.35M	Buy	201,080 +4,354	+2%	+$195K	0.61%	34
2024 Q1	$10.7M	Buy	196,726 +35,159	+22%	+$1.79M	0.86%	22
2023 Q4	$8.29M	Buy	161,567 +37,853	+31%	+$1.99M	0.74%	26
2023 Q3	$7.18M	Sell	123,714 -1,980	-2%	-$121K	0.7%	28
2023 Q2	$8.04M	Sell	125,694 -3,431	-3%	-$230K	0.77%	23
2023 Q1	$8.95M	Buy	129,125 +398	+0.3%	+$28.1K	0.93%	18
2022 Q4	$9.26M	Sell	128,727 -3,527	-3%	-$266K	1.01%	19
2022 Q3	$9.4M	Buy	132,254 +2,893	+2%	+$210K	1.04%	14
2022 Q2	$9.96M	Sell	129,361 -261	-0.2%	-$19.9K	1.04%	14
2022 Q1	$9.47M	Buy	129,622 +1,349	+1%	+$90.6K	0.85%	19
2021 Q4	$8M	Sell	128,273 -1,034	-0.8%	-$60.7K	0.71%	24
2021 Q3	$7.53M	Sell	129,307 -32,387	-20%	-$2.13M	0.68%	26
2021 Q2	$10.8M	Buy	161,694 +910	+0.6%	+$59.3K	1.55%	8
2021 Q1	$10.1M	Sell	160,784 -3,213	-2%	-$200K	1.22%	11
2020 Q4	$10.2M	Sell	163,997 -26,843	-14%	-$1.65M	1.34%	10
2020 Q3	$11.5M	Sell	190,840 -2,869	-1%	-$173K	2.09%	6
2020 Q2	$11.4M	Sell	193,709 -8,237	-4%	-$493K	3.71%	4
2020 Q1	$11.3M	Sell	201,946 -1,265	-0.6%	-$77.3K	3.37%	3
2019 Q4	$13M	Buy	+203,211	New	+$11.6M	3.51%	3

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Transcend Capital Advisors's BMY Position: Q2 2026 in Review

Transcend Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.6% in Q2 2026, buying an estimated $50.3K and bringing the position to 55,185 shares worth $3.18M. The position accounts for 0.21% of the portfolio, ranked #90.

Transcend Capital Advisors first reported a position in BMY in Q4 2019 and has held it in 27 quarters since. The position peaked at $13M in Q4 2019. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Transcend Capital Advisors held 55,185 shares of Bristol-Myers Squibb worth $3.18M as of Q2 2026.
Transcend Capital Advisors bought 876 Bristol-Myers Squibb shares in Q2 2026, an estimated $50.3K.
Bristol-Myers Squibb made up 0.21% of Transcend Capital Advisors's portfolio in Q2 2026, its #90 holding.
Transcend Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 27 quarters since.
Transcend Capital Advisors's Bristol-Myers Squibb position peaked at $13M in Q4 2019.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.